A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283

Sponsor
GlaxoSmithKline
Study ID
NCT07712393
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • GSK5784283 — DRUG
    GSK5784283 will be administered.

Study Details

The purpose of this study is to compare how two different formulations of the study medicine (GSK5784283) move through the body over time (pharmacokinetic \[PK\] study) in healthy adults. The aim of the study is to see how the body processes GSK5784283 and determine if the study medicine is safe, how well it is tolerated by the body and if the study medicines being tested work in the body in the same way.

Key Dates

First listed
Jul 17, 2026
Start date
Jul 17, 2026
Status verified
Jul 2026
Primary completion
Apr 30, 2027
Completion
May 3, 2027

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: GSK5784283 Test Formulation
  • Experimental: GSK5784283 Reference Formulation

Primary Outcome Measure

Maximum Observed Concentration (Cmax) of GSK5784283 Serum Samples [ Time Frame: Pre-dose and up to 253 days post dose ]

Central Contacts

Find similar trials

Nationwide
Asthma trialsPulmonology trialsLung disease trials

Related Studies